ClinicalTrials.gg
CompletedNCT06799546Updated Dec 22, 2025

A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy

A Phase 3 interventional study of HSK39297 tablets and Eculizumab Injection in PNH, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of HSK39297 tablets compared to eculizumab in Patients with PNH who Are Naive to Complement Inhibitor Therapy.

02

Conditions studied

  • PNH
03

In context

Lead sponsor

Haisco Pharmaceutical Group Co., Ltd. is the lead sponsor of 118 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 and ≤ 75 years, Male and female patients;
  2. Diagnosis of PNH based on flow cytometry with clone size > 10% by granulocytes;
  3. Have not received complement inhibitor treatment;
  4. Blood LDH values > 1.5 × (ULN) ;
  5. level \< 10 g/dL at screening.

Exclusion criteria

Exclusion Criteria:

  1. Hereditary or acquired complement deficiency;
  2. Active primary or secondary immunodeficiency;
  3. History of splenectomy, bone marrow/ hematopoietic stem cell or solid organ transplants;
  4. History of recurrent invasive infections caused by encapsulated organisms( e.g. meningococcus or pneumococcus) or Mycobacterium tuberculosis;
  5. Patients with laboratory evidence of bone marrow failure (reticulocytes \< 100x10\^9/L, or \< 30x10\^9/L or neutrophils \< 0.5x10\^9/L) ;
  6. Active systemic infection within 2 weeks prior to study drug administration;
  7. History of serious comorbidities that have been determined to be unsuitable for participation in the study.
  8. Pregnant or Lactating women.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    HSK39297 tablets

    Drug: HSK39297 tablets

  • Active comparator
    Eculizumab Injection

    Drug: Eculizumab Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving hemoglobin levels ≥ 12 g/dL at least on three out of four measurements in the absence of red blood cell transfusions

    Time frame: Between Week 18 and Week 24

Secondary outcomes

  1. Proportion of participants with increase in hemoglobin levels from baseline of ≥20 g/L at least on three out of four measurements in the absence of red blood cell transfusions

    Time frame: Between Week 18 and Week 24

  2. Proportion of participants who did not receive blood transfusion.

    Time frame: Between Week 2 and Week 24

  3. Change from baseline in hemoglobin

    Time frame: Baseline, week 18 to 24

  4. Change From Baseline in Reticulocyte Count

    Time frame: Baseline, week 18 to 24

  5. Percent change from baseline in LDH

    Time frame: Baseline, week 18 to 24

  6. Change from baseline in FACIT-Fatigue score

    Time frame: Baseline, week 18 to 24

  7. Rate of breakthrough hemolysis (BTH)

    Time frame: 24 weeks

  8. Proportion of participants with Major Adverse Vascular Events (MAVEs)

    Time frame: 24 weeks

07

Study locations

2 sites
  • The First Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210029, China
  • The First Affiliated Hospital, College of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310003, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in Nov 2025, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2025
First posted
Jan 29, 2025
StartActual
Feb 13, 2025
Primary completionActual
Nov 5, 2025
CompletionActual
Nov 5, 2025
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06799546
Responsible party
Sponsor
First posted
Jan 29, 2025
Start date
Feb 13, 2025
Primary completion
Nov 5, 2025
Completion
Nov 5, 2025
Last update
Dec 22, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK39297

Start the discussion